Bristol Myers Squibb (BMS) has formed a broad partnership with Hengrui Pharma in a deal potentially worth up to $15.2 billion. The agreement involves an upfront payment of $600 million to advance 13 early-stage programs across oncology, hematology, and immunology.
Capitalizing on clinical development efficiency A key driver of this collaboration is BMS’s objective to tap into Hengrui’s rapid clinical execution capabilities in China. Industry data indicates that the timeline from discovery to clinical trial filing in China can be 50% to 70% faster than in other regions. By utilizing this speed, BMS aims to reach clinical proof of concept faster, facilitating more informed and timely development decisions.
Asset exchange and operational synergy The deal outlines a strategic swap of pharmaceutical assets and geographic rights:
-
BMS Rights: Secured ex-China rights to four oncology and hematology assets from Hengrui. The two companies will also jointly discover and develop five additional drug candidates.
-
Hengrui Rights: Granted rights to four of BMS’s immunology assets in China, Hong Kong, and Macau. The Shanghai-based firm will take full responsibility for early human clinical development in these territories.
This partnership provides BMS with a strengthened pipeline and an accelerated development cycle. For Hengrui, the alliance offers access to BMS’s advanced drug discovery engine and global regulatory and commercial infrastructure. This move follows a series of high-profile international collaborations for Hengrui, including previous multi-billion dollar deals with GSK and Merck.